US Patent 10905690 Treatment of congenital adrenal hyperplasia
Patent 10905690 was granted and assigned to Neurocrine Biosciences on February, 2021 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 10905690 Treatment of congenital adrenal hyperplasia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.